2011•The LancetRequires access

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Jean‐Michel Molina, Pedro Enrique Cahn, Beatriz Gilda Jegerhorn Grinsztejn, Adriano Lazzarin, Anthony Mills, Michael S. Saag, Khuanchai Supparatpinyo, Sharon Lynn Walmsley, Herta M. Crauwels, Laurence T. Rimsky, Simon Vanveggel, Katia Boven

Open publisher page 404 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 404 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Rilpivirine, Emtricitabine, Efavirenz, Medicine, Viral load, Internal medicine, Regimen, Reverse-transcriptase inhibitor